Free-text search
Articles per year:
Content Types
-
Leqembi Iqlik launches as start‑dose option
The Alzheimer’s drug Leqembi, discovered by the Swedish company BioArctic and developed by Eisai, has now been launched in the United States as a subcutaneous treatment for both initiation and maintenance therapy
-
Cyberattacks surge – the medtech companies hit this year
Healthcare has long been a target for cyberattacks, resulting in operational disruption and the theft of sensitive data. This year, however, growing numbers of hackers have turned their attention to another target: medtech companies.
-
BioArctic chair: “First, you need to know where you’re going”
He has been a researcher, doctor, investor and business leader. But when Eugen Steiner explains BioArctic’s success, he keeps coming back to the same thing: its vision. Speaking to Life Science Focus, he discusses CEO recruitment, the founders’ determination and why Sweden risks falling behind in clinical research.
-
Study: Nearly 90% of biomedical papers show signs of AI assistance
The use of AI in scientific writing may be far more widespread than previous estimates have suggested. In a new study, almost nine out of ten biomedical papers from December 2025 showed linguistic signs of AI assistance, Nature reports.
-
Sanofi Sweden: ”We will work for more clinical trials”
Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact. Sweden Country Manager Daniel Sandgren hopes that will remain the case – yet he also sees clouds on the horizon.“Sweden risks losing its strong position in clinical trials”, he says in an interview.
-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In Sweden, 24 cases of the disease have so far been reported in an ongoing outbreak linked to a music festival. In the shadow of growing skepticism and declining vaccination coverage, measles – which has claimed millions of lives throughout history – is making a comeback.
-
“We develop vaccines no one else is developing”
Vaccines delivered via patches rather than injections. Future solutions could fundamentally reshape global health. Meet the man leading efforts to distribute vaccines where the need is greatest.
-
BioArctic steps into cancer research with new collaboration
BioArctic has entered a research collaboration with the Swedish‑Japanese company Mesenkia Therapeutics, marking the company’s first step into the oncology field.
-
Life sciences fuel Greater Copenhagen's economic growth
The expansion of the life sciences sector on the Danish side of the Øresund is a key reason why the Danish-Swedish Greater Copenhagen region has emerged as one of Northern Europe's strongest growth hubs.
-
Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
Tobacco for cancer, heroin for coughs, mercury for teething babies. Humanity’s path towards today’s evidence‑based medicine has been lined with strange misjudgements, outright quackery and “cures” that often caused more harm than good.
-
“Ozempic babies” – myth or reality?
Have weight-loss drugs such as Ozempic led to a rise in unplanned pregnancies? Life Science Sweden takes a closer look.
-
Hacker group claims Chinese bid for stolen Novo data
Earlier this year, Novo Nordisk was hit by a high‑profile data breach in which a large amount of sensitive information was stolen. Now a hacker group claims that it was offered millions of dollars for the stolen data from a Chinese company – but instead published the information openly on the internet.
-
Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer
Eli Lilly has until now had the US market for tau PET imaging in Alzheimer’s disease to itself. The pharmaceutical giant is now facing competition after the FDA approved radiopharmaceutical company Lantheus Holdings’s Tauklarify.
-
AstraZeneca scraps late‑stage study – and reports dual successes in lung cancer
AstraZeneca is discontinuing a global Phase III trial that has been evaluating the antibody volrustimig for non‑small cell lung cancer after the chances of success were deemed low. At the same time, the company is reporting promising data for two other lung‑cancer candidates.
-
Life Science Nordic launches – bringing Nordic life science news under one roof
Welcome to Life Science Nordic – your source for the news and insights shaping the Nordic life science and medtech industries. We provide independent, in-depth journalism covering developments across the Nordic market.
-
Hansa chair: “Too many boards spend far too much time looking inwards”
Following a change of chief executive and a sharper strategic focus, Hansa Biopharma is entering a decisive phase in the US market. As the company prepares for what comes next, chair Peter Nicklin is clear about his own role: to lead the board, but never dominate it.
-
Gold Rush in Oral Peptides: “Everybody Wants In”
After Ozempic, pharmaceutical companies are racing toward the next big revolution: peptides that can be swallowed as easily as they can be injected. Cyprumed is building the technology to get them there.
-
Phase III win for LSD‑based anxiety drug
An LSD‑based drug candidate for anxiety disorders is reported to show strong results in late‑stage clinical testing.
-
CF drug flops in phase II — shares collapse
A new experimental treatment for cystic fibrosis failed unexpectedly in phase II — and Sionna Therapeutics’ share price dropped by more than 90 percent.
-
XVIVO’s heart technology receives CE certificates
XVIVO has been granted CE certification for its preservation and transport system for donor hearts — allowing it to be used clinically in Europe. ”This is a proud and defining moment for everyone at XVIVO”, said CEO Christoffer Rosenblad.
-
Carola Lemne: “You only know afterwards whether you made the right choice”
Choosing the right chief executive is one of a board’s most difficult tasks – but far from its only one. Carola Lemne, chair of research company Irlab Therapeutics, talks about failed CEO appointments, strategic choices and why Sweden’s life science
-
Elicera reports strong CAR‑T-Data – shares rise
The Swedish CAR‑T developer Elicera saw its share price surge following an update on the company’s ongoing lymphoma study.
-
Gustav Ceder: ”Hälsodata är Sveriges nya guld”
”Det här kommer att vara guld för Sverige.” Så sa socialminister Jakob Forssmed när jag stötte på honom på en solvarm bakgata i Visby, mellan kullerstenar och nästa seminarium. Almedalen i ett nötskal, skriver Gustav Ceder i en krönika.
-
Hann du läsa det här? Redaktionen tipsar
I solstolen, på tågresan eller i hängmattan kan det bli tid över för läsning. Här tipsar vi om några av de texter Life Science Sweden publicerat tidigare i år.
BREAKING